Azenta Past Earnings Performance
Past criteria checks 0/6
Azenta's earnings have been declining at an average annual rate of -29.1%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been declining at an average rate of 2.2% per year.
Key information
-29.1%
Earnings growth rate
-29.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -2.2% |
| Return on equity | -0.7% |
| Net Margin | -2.7% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?
Apr 27
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
Apr 05Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price
Dec 28Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?
Nov 07At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?
Sep 13Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Aug 09Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?
Jun 01Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)
May 11Is Azenta, Inc. (NASDAQ:AZTA) Worth US$42.5 Based On Its Intrinsic Value?
Mar 30Azenta: Putting Its Cash Hoard To Use
Oct 02Azenta to acquire vaccine cold chain firm B Medical Systems for €410M
Aug 08Brasada Capital - Azenta Life Sciences: No Ordinary Company
Jul 26Azenta stock falls postmarket as prelim Q3 revenue misses Street estimates
Jul 13Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
May 05Should You Think About Buying Azenta, Inc. (NASDAQ:AZTA) Now?
Apr 14Revenue & Expenses BreakdownBeta
How Azenta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 641 | -17 | 297 | 35 |
| 30 Sep 23 | 665 | -13 | 311 | 34 |
| 30 Jun 23 | 630 | -21 | 307 | 33 |
| 31 Mar 23 | 597 | -26 | 289 | 30 |
| 31 Dec 22 | 594 | -25 | 279 | 29 |
| 30 Sep 22 | 555 | -11 | 247 | 28 |
| 30 Jun 22 | 555 | -28 | 267 | 26 |
| 31 Mar 22 | 551 | -23 | 267 | 25 |
| 31 Dec 21 | 535 | -29 | 261 | 24 |
| 30 Sep 21 | 514 | -29 | 252 | 22 |
| 30 Jun 21 | 114 | -69 | 183 | -10 |
| 31 Mar 21 | 205 | -53 | 185 | -2 |
| 31 Dec 20 | 296 | -37 | 183 | 9 |
| 30 Sep 20 | 389 | -26 | 190 | 18 |
| 30 Jun 20 | 850 | 41 | 232 | 59 |
| 31 Mar 20 | 834 | 28 | 224 | 59 |
| 31 Dec 19 | 812 | 16 | 217 | 58 |
| 30 Sep 19 | 334 | -61 | 157 | 17 |
| 30 Jun 19 | 741 | 3 | 194 | 54 |
| 31 Mar 19 | 710 | 7 | 182 | 51 |
| 31 Dec 18 | 668 | 72 | 170 | 49 |
| 30 Sep 18 | 632 | 68 | 163 | 47 |
| 30 Jun 18 | 488 | 35 | 154 | 41 |
| 31 Mar 18 | 498 | 47 | 149 | 40 |
| 31 Dec 17 | 510 | -2 | 146 | 40 |
| 30 Sep 17 | 527 | 11 | 141 | 40 |
| 30 Jun 17 | 669 | 56 | 136 | 46 |
| 31 Mar 17 | 634 | 47 | 132 | 47 |
| 31 Dec 16 | 600 | -51 | 127 | 49 |
| 30 Sep 16 | 434 | -85 | 116 | 44 |
| 30 Jun 16 | 549 | -73 | 123 | 52 |
| 31 Mar 16 | 546 | -74 | 119 | 52 |
| 31 Dec 15 | 550 | 12 | 117 | 52 |
| 30 Sep 15 | 553 | 14 | 114 | 52 |
| 30 Jun 15 | 529 | 8 | 112 | 53 |
| 31 Mar 15 | 502 | -3 | 112 | 54 |
| 31 Dec 14 | 489 | -3 | 111 | 54 |
| 30 Sep 14 | 483 | 1 | 110 | 53 |
| 30 Jun 14 | 471 | 3 | 107 | 51 |
| 31 Mar 14 | 464 | 10 | 102 | 49 |
| 31 Dec 13 | 448 | 5 | 97 | 48 |
| 30 Sep 13 | 422 | -7 | 97 | 46 |
| 30 Jun 13 | 431 | 107 | 96 | 45 |
Quality Earnings: AZTA is currently unprofitable.
Growing Profit Margin: AZTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AZTA is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare AZTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZTA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: AZTA has a negative Return on Equity (-0.71%), as it is currently unprofitable.